ReviewCancer treatment and research2015
Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.
Review in Cancer treatment and research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- The evidence for the use of peripheral blood indices in the diagnosis of breast cancer.The Journal of international medical research · 2026Review
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- High-density lipoproteins. Part 2. Impact of disease states on functionality.American journal of preventive cardiology · 2025Article
- Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.ACS applied materials & interfaces · 2025Article
- The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024Review
- Synthetic high-density lipoprotein (sHDL): a bioinspired nanotherapeutics for managing periapical bone inflammation.International journal of oral science · 2024Article
- Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities.AAPS PharmSciTech · 2023Review
- HDL-Based Therapy: Vascular Protection at All Stages.Biomedicines · 2023Review
- Low-density lipoprotein: a versatile nanoscale platform for targeted delivery.Nanoscale advances · 2023Review
- Simultaneous Noninvasive Detection and Therapy of Atherosclerosis Using HDL Coated Gold Nanorods.Diagnostics (Basel, Switzerland) · 2022Article
- Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential.Drug delivery · 2021Review
- Article
- α-Mangostin Nanoparticles Cytotoxicity and Cell Death Modalities in Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2021Review
- Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics.Current research in pharmacology and drug discovery · 2021Review
- Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.Surgery · 2019Article
- Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency.Scientific reports · 2019Article
- Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.Nano research · 2018Article
- Recent Progress in Metal-Based Nanoparticles Mediated Photodynamic Therapy.Molecules (Basel, Switzerland) · 2018Review
- Article
- HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
High-density lipoproteins (HDL) are diverse natural nanoparticles that carry cholesterol and are best known for the role that they play in cardiovascular disease. However, due to their unique targeting capabilities, diverse molecular cargo, and natural functions beyond cholesterol transport, it is becoming increasingly appreciated that HDLs are critical to cancer development and progression. Accordingly, this chapter highlights ongoing research focused on the connections between HDL and cancer in order to design new drugs and targeted drug delivery vehicles. Research is focused on synthesizing biomimetic HDL-like nanoparticles (NP) that can be loaded with diverse therapeutic cargo (e.g., chemotherapies, nucleic acids, proteins) and specifically targeted to cancer cells. Beyond drug delivery, new data is emerging that HDL-like NPs may be therapeutically active in certain tumor types, for example, B cell lymphoma. Overall, HDL-like NPs are becoming increasingly appreciated as targeted, biocompatible, and efficient therapies for cancer, and may soon become indispensable agents in the cancer therapeutic armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.